|
|
Diabetic Nephropathy
|
|
Diabetic Nephropathy
Don’t Forget Your Vitamins! Jan 23, 2006
...magnesium), appear to improve kidney function in patients with type 2 diabetes and proved useful in addressing a common complication called diabetic nephropathy ...
- Saturday Evening Post,
Galway to hold cardiovascular medicine symposium Jan 20, 2006
Diabetic Patients; and Dr Liam Plant, consultant nephrologist, Cork University Hospital, who will provide an update on Diabetic Nephropathy and Cardiovascular ...
- Irish Medical News,
Ron Bentsur Accepts Position As CEO of XTL Biopharmaceuticals, Ltd ... Jan 2, 2006
Keryx's lead compound under development is KRX-101 (sulodexide), a first-in-class, oral heparinoid compound for the treatment of diabetic nephropathy, a life ...
- dBusinessNews New York (press release),
Empiricus: our clinical journal commentator 23 Nov 2005
The first trial of a drug called ruboxistaurin in patients with diabetic nephropathy has shown a reduction in albuminuria and stabilisation of declining kidney ...
- AustralianDoctor.com (subscription),
SPP301 Phase IIb Results in Diabetic Nephropathy Presented at ASN Nov 11, 2005
12 /PRNewswire-FirstCall/ -- Speedel (SWX: SPPN) announced today that positive Phase IIb results of SPP301 in diabetic nephropathy (diabetic kidney disease ...
- PR Newswire (press release),
Vitamins and Minerals Can Help in Diabetic Nephropathy Oct 24, 2005
Beheshti University of Medical Sciences, Tehran and colleagues note that studies indicate that antioxidants can be helpful in diabetic nephropathy and there is ...
- About - News & Issues,
Keryx Announces Positive Final Results from Phase 2 Clinical Study ... Nov 11, 2005
An exploratory, randomized, double-blind, multiple dose study of KRX-101 (sulodexide gelcaps) for the treatment of type 2 diabetic nephropathy patients with ...
- PR Newswire (press release),
CuraGen Presents Phase I Results on CR002 at ASN Renal Week 2005 Nov 14, 2005
...to explore its role in potentially helping patients with kidney inflammation caused by PDGF-D, including IgA nephropathy and diabetic nephropathy." Data on 40 ...
- PR Newswire (press release),
Keryx Biopharmaceuticals, Inc, Announces Final Phase II Data ... Oct 24, 2005
Collaborative Study Group, will be presenting final data from the Company's Phase II study of KRX-101 (oral sulodexide gelcap) for diabetic nephropathy at the ...
- PR Newswire (press release),
SPP301 Phase IIb Data to Be Presented at American Society of ... Oct 27, 2005
28 /PRNewswire/ -- Speedel (SWX: SPPN) announced today that data from its Phase IIb study of SPP301 in the treatment of diabetic nephropathy will be presented ...
- PR Newswire (press release),
SPP301 Phase IIb Data to Be Presented at American Society of ... Oct 28, 2005
NJ, October 28, 2005 /PRNewswire/ -- Speedel announced today that data from its Phase IIb study of SPP301 in the treatment of diabetic nephropathy will be ...
- PharmaLive.com (press release),
FibroGen Appoints Russell H. Ellison, MD, MSc, Vice President of ... Nov 10, 2005
...will focus on expansion of the Company's clinical development team and rapid advancement of key clinical programs in anemia, diabetic nephropathy, and dermal ...
- PharmaLive.com (press release),
Academia, industry join forces to honour world-renowned Canadian ... Nov 15, 2005
...“We are in the midst of a pandemic of diabetic nephropathy and we are going to see an increasing number of these patients with end-stage renal disease ...
- News@UofT,
Low-Dose Epoetin Beta Offers Improved Renal Anaemia Management for ... Nov 11, 2005
...pressure. Diabetic nephropathy (22.9%) and glomerulonephritis (27.0%) were the top two reasons for patients requiring haemodialysis. ...
- DG News
Hypertension and Diabetic Kidney Disease - Prevalence, current ... Oct 24, 2005
The commercial potential for successful new agents is substantial as existing therapies do not halt the progression of diabetic nephropathy to end stage renal ...
- Pharmaceutical Business Review
Keryx Biopharmaceuticals to Present at Bear Stearns SMid-Cap ... Nov 4, 2005
Keryx's lead compound under development is KRX-101 (sulodexide), a first-in-class, oral heparinoid compound for the treatment of diabetic nephropathy, a life ...
- PR Newswire (press release),
Drugs in Development Sep 21, 2005
...has started a Phase III study of SPP301, a once-a-day oral endothelin A receptor antagonist in the indication of diabetic nephropathy. ...
- R&D Directions (subscription)
Pilot Study of Ruboxistaurin Showed Favorable Effects on Kidney ... Sep 12, 2005
...a one-year pilot study examining the effect of ruboxistaurin mesylate in persons with type 2 diabetes and kidney disease (also known as "diabetic nephropathy ...
- news aktuell (Pressemitteilung)
King Pharmaceuticals Reports FDA Acceptance of Altace(R) ... Sep 22, 2005
...controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. ...
- PR Newswire (press release)
CME programme on diabetes Sep 17, 2005
Department of Nephrology associate professor Dr Ramachandra, in his guest lecture on ‘‘recent advances in diabetic nephropathy’’ elaborated that ...
- Newindpress
Keryx to Present at Oppenheimer Diabetes Conference, Tomorrow ... Sep 6, 2005
...the Company's lead compound under development, is currently being evaluated in a Phase III/IV clinical program for the treatment of diabetic nephropathy. ...
- PR Newswire (press release)
Keryx to Present at the Bear Stearns 18th Annual Healthcare ... Sep 9, 2005
Keryx' lead compound under development is KRX-101 (sulodexide), a first-in-class, oral heparinoid compound for the treatment of diabetic nephropathy, a life ...
- PR Newswire (press release)
New Type of Hypertension Treatment Effective and Well Tolerated Sep 3, 2005
...therapy and in phase II as combination therapy in patients with mild-to-moderate hypertension, and in phase II trials in patients with diabetic nephropathy. ...
- I-Newswire.com (press release)
Advanced glycation end products and the kidney Sep 30, 2005
These effects are most prominent in diabetic nephropathy, but they also contribute to renal pathophysiology in other nondiabetic renal diseases. ...
- AJP-Renal Physiology
Speedel Gains Stock Listing In Zurich But Raises No Cash Sep 13, 2005
Speedel itself moved SPP301, an endothelin receptor antagonist, into a pivotal Phase III trial in diabetic nephropathy in July. ...
- BioWorld Online (subscription)
Establishment of a Diabetic Mouse Model with Progressive Diabetic ...Jul 27, 2005
...mice that overexpress inducible cAMP early repressor (ICER I ) in pancreatic ß cells are a good model to study the pathogenesis of diabetic nephropathy. ...
- Am J Pathology (subscription)
Speedel Starts Phase III Study of SPP301 in Diabetic NephropathyJul 6, 2005
...start of its Phase III study for SPP301, its once-a-day oral endothelin A receptor antagonist (ERA) in the indication of diabetic nephropathy (diabetic kidney ...
- Yahoo News
Peripheral Total and Differential Leukocyte Count in Diabetic ...Jul 9, 2005
...potential metabolic confounding factors were analyzed with linear and logistic regression to calculate the effects of leukocyte count on diabetic nephropathy. ...
- RedNova.com
Speedel Begins Pivotal Trial Of SPP301 In Diabetic NephropathyJul 12, 2005
Four months after reporting positive results from a Phase IIb trial of its endothelin A receptor antagonist, SPP301, in diabetic nephropathy, Speedel Group AG ...
- BioWorld Online (subscription)
Investigations for Diabetes MellitusJul 29, 2005
It can be estimated by immunoturbidometry and nephelometry: 30 – 40 per cent of Type I {IDDM} diabetes mellitus develop diabetic nephropathy with a strong ...
- Express Healthcare Management
Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Second ...Jul 29, 2005
Keryx's lead compound under development is KRX-101 (sulodexide), a first-in-class, oral heparinoid compound for the treatment of diabetic nephropathy, a life ...
- PrimeZone
Actelion announces Half Year financial results 2005Jul 29, 2005
...data generated in the proof-of-concept program, testing its urotensin-II receptor antagonist, palosuran, in the indication diabetic nephropathy did not support ...
- PharmaLive.com
Region-Specific Alterations of Adenosine Receptors Expression ...Jul 27, 2005
...and tissue distribution, correspond to abnormalities characteristic of the diabetic kidney, suggesting involvement in pathogenesis of diabetic nephropathy.
- Am J Pathology (subscription)
HemoCue Introduces a Point-of-Care Urine Albumin System for ...Jul 25, 2005
Microalbuminuria is a powerful predictor for the future development of diabetic nephropathy and cardiovascular disease. Diabetic ...
- Yahoo News
Soy is good for your kidneys and heartJul 19, 2005
Diabetic nephropathy is kidney disease that develops as a result of diabetes and is the primary cause of chronic renal failure in the United States and other ...
- Health Sentinel
Increased Demand For Astaxanthin to be Met By Fuji Health Science ...Jul 25, 2005
In addition, the company supports ongoing research on the health benefits of astaxanthin in such areas as eye fatigue and diabetic nephropathy.
- NPIcenter
Care for your kidneysJul 16, 2005
Diabetes mellitus, coupled with high blood pressure and cigarette smoking, is the leading cause of kidney disease (diabetic nephropathy) in many countries. ...
- Malaysia Star
Keryx plans to raise $70mJul 12, 2005
18%. Keryx’s flagship product, KRX-101 (Sulodexide), is an oral treatment for diabetic nephropathy, a kidney disease. Another ...
- Globes Online
Endocrinology & Metabolism News, July 2005Jul 6, 2005
Pancreas transplant, by restoring sustained normoglycemia, improved diabetic nephropathy (Diabetes Care (June 2005) 28:1366) and retinopathy (Transpl Int (May ...
- Journal of Clinical Endocrinology and Metabolism
This page is updated on a monthly basis if relevant articles are available. If you are looking for further information on
Diabetic Nephropathy
you may want to try searching the Internet using the Google search box below.
|
|
|
